Prospecting the influenza hemagglutinin to develop universal vaccines

Clinical Infectious Diseases

Volumn 52, Issue 8, 2011, Pages 1010-1012

  Donis, Ruben O ^a   Cox, Nancy J ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNITY; IMMUNOLOGICAL MEMORY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MORTALITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; SEASONAL INFLUENZA; TREATMENT RESPONSE; UNITED STATES; VIRUS PARTICLE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 79953896609     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir129     Document Type: Editorial

References (18)

1. Leung GM, Nicoll A. Reflections on pandemic (H1N1) 2009 and the international response. PLoS Med 2010; 7:e1000346.
2. SteelFisher GK, Blendon RJ, Bekheit MM, Lubell K. The public's response to the 2009 H1N1 influenza pandemic. N Engl J Med 2010; 362:e65.
3. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr Influenza 2010; RRN1153.
4. Capua I, Kajaste-Rudnitski A, Bertoli E, Vicenzi E. Pandemic vaccine preparedness- have we left something behind? PLoS Pathog 2009; 5:e1000482.
5. Cohen J, Enserink M. Pandemic vaccine "will arrive too late for many," CDC concedes. Sci Insider 2009. Available at: http:// news.sciencemag.org/scienceinsider/2009/10/ pandemic-vaccin-2.html. Accessed 22 February 2011.
6. PCAST/White-House. Report to the president on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza. Washington,DC, 2010. Available at: http://www. whitehouse.gov/sites/default/ files/microsites/ ostp/PCAST-Influenza-Vaccinology-Report. pdf Accessed 22 February 2011.
7. Edwards KM, Sabow A, Pasternak A, Bo-slego JW. Strategies for broad global access to pandemic influenza vaccines. Curr Top Microbiol Immunol 2009; 333:471-93.
8. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:1389-91.
9. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67:2552-8. (Pubitemid 23118850)
10. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-73.
11. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM1 memory B cells. PLoS One 2008; 3:e3942.
12. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-51.
13. Sui J, Sheehan J, Hwang WC, et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 2011; (in this issue).
14. Corti D, Suguitan AL Jr., Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73.
15. Wilson IA, Cox NJ. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990; 8:737-71. (Pubitemid 20135645)
16. Bommakanti G, Citron MP, Hepler RW, et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 2010; 107:13701-6.
17. Bommakanti G, Citron MP, Hepler RW, et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 2010; 107: 13701-13706.
18. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010; 107:18979-84.